

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 Claims 1-2 (Canceled)

1 3. (Original) A system for averting undesirable drug interaction between a
2 drug and concomitant drug(s), both of which are metabolized by the same molecular
3 species of drug-metabolizing enzyme in humans, or between a drug and concomitant
4 drug(s) that is metabolized by the molecular species of drug-metabolizing enzymes that is
5 inhibited by the said drug, which comprises timed-release control of the said drug or
6 control of the site of release of the said drug to the digestive tract.

1 4. (Original) A system for averting undesirable drug interaction between a
2 drug and concomitant drug(s), both of which metabolized by the drug metabolizing
3 enzyme CYP3A4, or between a drug that inhibits CYP3A4 and concomitant drug(s) that
4 is metabolized by CYP3A4, which comprises timed-release control of the said drug or
5 controlling release specifically in the lower digestive tract of the said drug.

1 Claims 5-6 (Canceled)

1 7. (Original) A drug preparation for averting undesirable drug interaction
2 on the *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo* metabolism
3 of the said drug in humans, which comprises timed-release control of the concomitant
4 drug or control of the site of release of the concomitant drug to the digestive tract.

1 8. (Original) A drug preparation for averting undesirable effects on the
2 blood concentration of a drug by concomitant drug(s) that inhibits the *in vivo* metabolism
3 of the said drug by CYP3A4 in humans, which comprises timed release control of the
4 said drug or controlling release specifically in the lower digestive tract of the concomitant
5 drug.

1 9. (Original) The drug preparation according to Claim 8, whereby the said
2 drug and the concomitant drug are a combination selected from anfentanyl, fentanyl,
3 sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin,
4 clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone,
5 midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
6 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,
7 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,
8 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
9 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
10 pimozone, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
11 fluvastatin, atorvastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
12 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
13 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
14 ondanteron, zolsetron, cisapride, cortisol, zonisamide, desmethyldiazepam, and
15 conivaptan.

1 Claims 10-11 (canceled)

1 12. (Original) A method for averting undesirable drug-interaction on the *in*
2 *vivo* kinetics of a drug by concomitant drug that inhibits the *in vivo* metabolism of the
3 said drug by drug-metabolizing enzymes in humans, comprising administering to patients
4 a drug preparation with which timed-release of the concomitant drug or release site of the
5 concomitant drug to the digestive tract is controllable.

1 13. (Original) A method for averting undesirable effects on the blood
2 concentration of a drug by concomitant drug that inhibits the *in vivo* metabolism of the
3 said drug by CYP3A4, comprising administering to patients a drug preparation with
4 which timed-release of the concomitant drug or release of the concomitant drug
5 specifically to the lower digestive tract is controllable.

1 14. (Original) The method according to Claim 13, whereby the said drug
2 and the concomitant drug are a combination selected from anfentanyl, fentanyl,

3 sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol, erythromycin,
4 clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole, dapsone,
5 midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
6 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,
7 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,
8 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
9 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
10 pimozone, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
11 fluvastatin, atorvastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
12 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
13 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
14 ondansetron, zolmitriptan, cisapride, cortisol, zonisamide, desmethyldiazepam, and
15 conivaptan.

C1
1 15. (Canceled)

cont.
1 16. (Previously added) A drug preparation for averting undesirable effects
2 on the blood concentration of a drug by concomitant drug(s) that inhibits the *in vivo*
3 metabolism of the said drug by CYP3A4 in humans, which comprises timed release
4 control of the said drug or controlling release specifically in the lower digestive tract of
5 the concomitant drug, whereby:

6 the said drug and the concomitant drug are a combination selected from
7 anfenbutyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,
8 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,
9 dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
10 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,
11 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,
12 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
13 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
14 pimozone, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
15 fluvastatin, atorvastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,

16 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
17 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
18 ondasteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and
19 conivaptan.

1 17. (Previously added) A drug preparation for averting undesirable drug
2 interaction on the *in vivo* kinetics of a drug by concomitant drug(s) that inhibits *in vivo*
3 metabolism of the said drug in humans, which comprises timed-release control of the
4 concomitant drug or control of the site of release of the concomitant drug to the digestive
5 tract whereby:

6 the said drug and the concomitant drug are a combination selected from
7 anfantanyl, fentanyl, sulfentanyl, cocaine, dihydrocodeine, oxycodone, tramadol,
8 erythromycin, clarithromycin, troleandomycin, azithromycin, itraconazole, ketoconazole,
9 dapsone, midazolam, triazolam, alprazolam, diazepam, zolpidem, felodipine, nifedipine,
10 nitrendipine, amlodipine, isradipine, nicardipine, nimodipine, nisoldipine, nildipine,
11 bepridil, diltiazem, verapamil, astemizole, terfenadine, loratidine, cyclosporine,
12 tacrolimus, rapamycin, amiodarone, disopyramide, lidocaine, propafenone, quinidine,
13 imipramine, amitriptyline, clomipramine, nafazodone, sertraline, trazodone, haloperidol,
14 pimozone, carbamazepine, ethosuximide, trimethadione, simvastatin, lovastatin,
15 fluvastatin, atrovastatin, etoposide, ifosfamide, paclitaxel, tamoxifen, taxol, vinblastine,
16 vincristine, indinavir, ritonavir, saquinavir, testosterone, prednisolone,
17 methylprednisolone, dexamethasone, proguanil, warfarin, finasteride, flutamide,
18 ondasteron, zatsetrone, cisapride, cortisol, zonisamide, desmethyldiazepam, and
19 conivaptan.

1 18. (Previously added) The system for averting undesirable drug
2 interaction of claim 3, wherein said drug and the concomitant drug are both metabolized
3 by the same molecular species of drug-metabolizing enzyme in humans.

1 19. (Previously added) The system for averting undesirable drug
2 interaction of claim 3, wherein the concomitant drug is metabolized by the molecular
3 species of the drug-metabolizing enzymes that is inhibited by the said drug.

1 20. (Previously added) The system for averting undesirable drug
2 interaction of claim 18, wherein said drug and the concomitant drug are both metabolized
3 by CYP3A4.

1 21. (Previously added) The system for averting undesirable drug
2 interaction of claim 19, the concomitant drug is metabolized by CYP3A4 and said drug
3 inhibits CYP3A4.

1 22. (New) The system for averting undesirable drug interaction between a
2 drug and concomitant drug(s) of claim 3, wherein the timed-release control of the said
3 drug is a member selected from the group consisting of insoluble membrane bursting-
4 type, cap breakaway-type, membrane permeation increasing-type and hydrogel layer
5 dissolving-type.

1 23. (New) The system for averting undesirable drug interaction between a
2 drug and concomitant drug(s) of claim 3, wherein control of the site of release of the said
3 drug to the digestive tract is accomplished using a member selected from the group
4 consisting of terms of drug metabolism, drug absorption, drug distribution, and drug
5 excretion.